Avails Medical, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenge of antibiotic resistance and health-care associated infections. Avails is developing intuitive, streamlined, standalone applications, all based on its proprietary electrical biosensor platform. Applications will include electrical pathogen quantification, antibiotic susceptibility testing (AST) and identification of certain forms of resistance expressed in bacteria and fungi directly from a positive blood culture. Avails platform will advance the in-vitro diagnostics market by enabling timely diagnostics-guided therapy, meaningfully reducing the time to most effective and targeted treatment. For the majority of infectious disease diagnoses, Avails is expected to reduce treatment decisions from days to several hours. Avails first product is expected to start clinical trials in early 2020.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
eQuant - standardized inoculum generator directly from positive blood culture
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):